185 related articles for article (PubMed ID: 34882192)
1. Cumulative Mortality and Factors Associated With Outcomes of Mucormycosis After COVID-19 at a Multispecialty Tertiary Care Center in India.
Choksi T; Agrawal A; Date P; Rathod D; Gharat A; Ingole A; Chaudhari B; Pawar N
JAMA Ophthalmol; 2022 Jan; 140(1):66-72. PubMed ID: 34882192
[TBL] [Abstract][Full Text] [Related]
2. Incidence, cumulative mortality and factors affecting the outcome of COVID-19-associated mucormycosis from Western India.
Vare AA; Yellambkar S; Farheen A; Nandedkar V; Bhombe SS; Shah R
Indian J Ophthalmol; 2021 Dec; 69(12):3678-3683. PubMed ID: 34827021
[TBL] [Abstract][Full Text] [Related]
3. Mortality and its determinants after an outbreak of post COVID-19 associated rhino-orbito-cerebral mucormycosis in Central India.
Nagarkar NM; Sahu V; Arora R; Pathak M; Shambharkar MS; Naveen P
Int Ophthalmol; 2023 Jul; 43(7):2363-2370. PubMed ID: 36645635
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
[TBL] [Abstract][Full Text] [Related]
5. Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India.
Yadav H; Sen S; Nath T; Mazumdar S; Jain A; Verma P; Gupta P
Indian J Ophthalmol; 2022 Jun; 70(6):2163-2168. PubMed ID: 35648004
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
[TBL] [Abstract][Full Text] [Related]
7. Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study.
Gandhi A; Narula A; Chandra S; Agarwal D; Mehta A; Nayak S; Arora S; Capoor MR
Int Ophthalmol; 2023 May; 43(5):1571-1580. PubMed ID: 36273362
[TBL] [Abstract][Full Text] [Related]
8. Rhino-orbital mucormycosis: Our experiences with clinical features and management in a tertiary care center.
Singh SP; Rana J; Singh VK; Singh R; Sachan R; Singh S; Jain S
Rom J Ophthalmol; 2021; 65(4):339-353. PubMed ID: 35087975
[No Abstract] [Full Text] [Related]
9. COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.
Abdorahimi M; Pakdel F; Salehi M; Alcazar-Fuoli L; Hashemi SJ; Daie Ghazvini R; Ahmadkhani F; Ahmadikia K; Abdollahi A; Debran JCS; Tabari A; Farrokh F; Mousavand A; Afarinesh Khaki P; Salami Khaneshan A; Ibrahim AS; Khodavaisy S
Mycopathologia; 2023 Oct; 188(5):783-792. PubMed ID: 37672164
[TBL] [Abstract][Full Text] [Related]
10. Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients.
Nair AG; Adulkar NG; D'Cunha L; Rao PR; Bradoo RA; Bapaye MM; Kothari A; Dave TV; Shinde CA
Orbit; 2021 Dec; 40(6):499-504. PubMed ID: 34338124
[TBL] [Abstract][Full Text] [Related]
11. Rhizopus homothallicus rhino-orbital-cerebral mucormycosis: Six cases from a tertiary care Centre, North India.
Gupta MK; Selvaraj S; Tilak R; Kumar N; Kumar R; Chakravarty J
Trop Med Int Health; 2023 Feb; 28(2):144-150. PubMed ID: 36517958
[TBL] [Abstract][Full Text] [Related]
12. Rise of the phoenix: Mucormycosis in COVID-19 times.
Ravani SA; Agrawal GA; Leuva PA; Modi PH; Amin KD
Indian J Ophthalmol; 2021 Jun; 69(6):1563-1568. PubMed ID: 34011742
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
Mrig S; Sardana K; Arora P; Narula V; Arora S; Kapoor A; Baruah RR; Sen P; Agarwal S; Sachdeva S; Dewan A; Panesar S
Am J Otolaryngol; 2022; 43(3):103465. PubMed ID: 35429848
[TBL] [Abstract][Full Text] [Related]
14. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
Seidel D; Simon M; Sprute R; Lubnow M; Evert K; Speer C; Seeßle J; Khatamzas E; Merle U; Behrens C; Blau IW; Enghard P; Haas CS; Steinmann J; Kurzai O; Cornely OA
Mycoses; 2022 Jan; 65(1):103-109. PubMed ID: 34655486
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 associated multisystemic mucormycosis from India: a multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome.
Sahu M; Shah M; Mallela VR; Kola VR; Boorugu HK; Punjani AAR; Kumar RV; Kumar S; Manusrut M; Kumar SCR; Rathod R; Babu DM; Gonuguntla HK; Yedlapati GK; Mallu GR; Reddy YS; Reddy VV; Alwala S; Bongu VK; Kamalesh A; Kumar RNK; Jaishetwar GS; Bagapally RS; Srinivas JS; Balasubramaniam A; Rajagopalan BK; Pullikanti B; Prakasham SP; Nimmala P; Nagaraju B; Sahoo PR;
Infection; 2023 Apr; 51(2):407-416. PubMed ID: 35922704
[TBL] [Abstract][Full Text] [Related]
16. Alternating pattern of rhino-orbital-cerebral mucormycosis with COVID-19 in diabetic patients.
Eker C; Tarkan O; Surmelioglu O; Dagkiran M; Tanrisever I; Yucel Karakaya SP; Ulas B; Onan E; Uguz AH; Ozdemir S
Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):219-226. PubMed ID: 35768700
[TBL] [Abstract][Full Text] [Related]
17. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
Wasiq M; K R; Gn A
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443518
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
[TBL] [Abstract][Full Text] [Related]
19. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report.
Veisi A; Bagheri A; Eshaghi M; Rikhtehgar MH; Rezaei Kanavi M; Farjad R
Eur J Ophthalmol; 2022 Jul; 32(4):NP11-NP16. PubMed ID: 33843287
[TBL] [Abstract][Full Text] [Related]
20. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran.
Pakdel F; Ahmadikia K; Salehi M; Tabari A; Jafari R; Mehrparvar G; Rezaie Y; Rajaeih S; Alijani N; Barac A; Abdollahi A; Khodavaisy S
Mycoses; 2021 Oct; 64(10):1238-1252. PubMed ID: 34096653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
